Related Experiment Video
Updated: May 24, 2025

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Transient bacteraemia secondary to imiquimod use as a treatment for cervical high-grade squamous intraepithelial
Caroline L P Muntinga1,2, Sophieke C H A van der Steen3, Edith M G van Esch1
1Department of gynecology and obstetrics, Catharina Ziekenhuis Eindhoven, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
Insights
Imiquimod cream for cervical lesions can cause severe side effects like distributive shock. Patients require close monitoring for adverse reactions during treatment for high-grade squamous intraepithelial lesions.
Area of Science:
- Gynecologic Oncology
- Dermatology
- Pharmacology
Background:
- Imiquimod is an immunomodulator used for cervical high-grade squamous intraepithelial lesions (cHSIL).
- While generally well-tolerated, imiquimod can cause significant side effects.
- Patient counselling regarding potential adverse events is crucial.
Observation:
- A patient using imiquimod for recurrent cHSIL developed distributive shock.
- The severe reaction occurred nearly three weeks after initiating treatment.
- No infectious etiology was identified for the patient's condition.
Findings:
- The patient recovered with conservative management.
- This case highlights the potential for severe, unexpected side effects from imiquimod.
- Distributive shock is a rare but serious adverse event associated with imiquimod therapy.
Implications:
- Healthcare providers must vigilantly monitor patients undergoing imiquimod treatment for cHSIL.
- Informed consent discussions should thoroughly cover the risk of severe side effects.
- Further research may be warranted to identify risk factors for severe imiquimod reactions.
Abstract:
Imiquimod is an immunomodulating cream used in the treatment of cervical high-grade squamous intraepithelial lesions (cHSIL). Side-effects are common and mostly well tolerated, but can be severe. A woman using imiquimod for recurrent cHSIL presented with signs of a distributive shock nearly three weeks after the start of imiquimod treatment, for which she was admitted to a medium care unit. No infectious source was identified. The woman recovered well with conservative treatment. This case demonstrates the importance of monitoring patients for side-effects during imiquimod treatment. Side-effects, including the possibility of severe side-effects, should be discussed during patient counselling on therapy options for cHSIL treatment.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Bacterial Signaling

